Bradley Canino
Stock Analyst at Stifel
(1.96)
# 3,153
Out of 5,006 analysts
88
Total ratings
31.65%
Success rate
-2.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Reinstates: Buy | $44 | $16.40 | +168.29% | 7 | Sep 10, 2025 | |
| JANX Janux Therapeutics | Reinstates: Buy | $45 | $22.76 | +97.72% | 3 | Sep 10, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $3.92 | +282.65% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $2.11 | -28.91% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $5.84 | +225.34% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $5.59 | +311.45% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $9.62 | +430.15% | 6 | Feb 12, 2025 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $9.80 | +93.88% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $47.81 | -12.14% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $22.15 | +80.59% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $83.85 | +61.00% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $14.41 | +38.79% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.47 | +304.86% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $1.59 | +528.93% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $94.27 | +5.02% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $2.28 | +514.04% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $57.55 | -4.43% | 4 | Feb 23, 2024 |
Syndax Pharmaceuticals
Sep 10, 2025
Reinstates: Buy
Price Target: $44
Current: $16.40
Upside: +168.29%
Janux Therapeutics
Sep 10, 2025
Reinstates: Buy
Price Target: $45
Current: $22.76
Upside: +97.72%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $3.92
Upside: +282.65%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $2.11
Upside: -28.91%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $5.84
Upside: +225.34%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $5.59
Upside: +311.45%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $9.62
Upside: +430.15%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $9.80
Upside: +93.88%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $47.81
Upside: -12.14%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $22.15
Upside: +80.59%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $83.85
Upside: +61.00%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $14.41
Upside: +38.79%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $2.47
Upside: +304.86%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $1.59
Upside: +528.93%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $94.27
Upside: +5.02%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $2.28
Upside: +514.04%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $57.55
Upside: -4.43%